What Malhotra Says Patients Should Know About Statins
Malhotra challenges the idea that lowering LDL explains every statin benefit and suggests anti-inflammatory or anti-clotting effects may contribute. He gives benefit and side-effect estimates from his interpretation of industry-sponsored trials, while stressing that he discusses statins rather than automatically rejecting them; these figures and interpretations should be checked with a qualified clinician and current guidance.
- He separates people without diagnosed disease from those with a previous heart attack
- He argues that absolute benefits are smaller than relative-risk messaging implies
- He claims quality-of-life side effects may be underrecognized and are often reversible
- He says higher-risk patients receive greater benefit than lower-risk patients
- He frames the choice as informed consent, not a universal instruction to stop treatment
“it's not that I'm saying don't take statins”
“the benefit of statins which I will give you in a second, right? is probably more likely because of those properties”